SEARCH:   Advanced

Blood, 1 March 2007, Vol. 109, No. 5, pp. 2165-2173. Prepublished online as a Blood First Edition Paper on November 2, 2006; DOI 10.1182/blood-2006-06-028092. This Article Full Text (PDF) Supplemental Tables and Figures All Versions of this Article: blood-2006-06-028092v1 109/5/2165    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sin, S.-H. Articles by Dittmer, D. P Search for Related Content PubMed PubMed Citation Articles by Sin, S.-H. Articles by Dittmer, D. P Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 15, 2006 Accepted October 5, 2006 Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling Sang-Hoon Sin, Debasmita Roy, Ling Wang, Michelle R Staudt, Farnaz D Fakhari, Dhavalkumar D Patel, David Henry, William J Harrington, Blossom A Damania, and Dirk P Dittmer* University of North Carolina at Chapel Hill University of Pennsylvania University of Miami * Corresponding author; email: ddittmer{at}med.unc.edu. The anti tumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations. Primary effusion lymphoma (PEL) appears concomitant with Kaposi's sarcoma as an AIDS and Kaposi's sarcoma-associated herpesvirus (KSHV) linked neoplasm. We find that (i) rapamycin is efficacious against PEL in culture and in a murine xenograft model; (ii) mTOR, it's activator Akt and its target p70S6 kinase are phosphorylated in PEL; (iii) rapamycin inhibits mTOR signaling as determined by S6 phosphorylation; (iv) KSHV transcription is unaffected; (v) inhibition of IL-10 signaling correlates with drug sensitivity; and (vi) addition of exogenous IL-10 or IL-6 can reverse the rapamycin growth arrest. This validates sirolimus as a new treatment option for PEL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. El-Salem, P. N. Raghunath, M. Marzec, X. Liu, M. Kasprzycka, E. Robertson, and M. A. Wasik Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas Am. J. Pathol., August 1, 2009; 175(2): 817 - 824. [Abstract] [Full Text] [PDF] E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis Clin. Cancer Res., February 15, 2009; 15(4): 1297 - 1307. [Abstract] [Full Text] [PDF] P. Armand, S. Gannamaneni, H. T. Kim, C. S. Cutler, V. T. Ho, J. Koreth, E. P. Alyea, A. S. LaCasce, E. D. Jacobsen, D. C. Fisher, et al. Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning J. Clin. Oncol., December 10, 2008; 26(35): 5767 - 5774. [Abstract] [Full Text] [PDF] P. Gasperini, S. Sakakibara, and G. Tosato Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis J. Leukoc. Biol., October 1, 2008; 84(4): 994 - 1000. [Abstract] [Full Text] [PDF] L. Wang and B. Damania Kaposi's Sarcoma-Associated Herpesvirus Confers a Survival Advantage to Endothelial Cells Cancer Res., June 15, 2008; 68(12): 4640 - 4648. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020